- Home
- FWRG vs CRMD Comparison
FWRG vs CRMD Comparison
Compare FWRG & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWRG
- CRMD
- Stock Information
- Founded
- FWRG 1983
- CRMD 2006
- Country
- FWRG United States
- CRMD United States
- Employees
- FWRG N/A
- CRMD N/A
- Industry
- FWRG Restaurants
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- FWRG Consumer Discretionary
- CRMD Health Care
- Exchange
- FWRG Nasdaq
- CRMD Nasdaq
- Market Cap
- FWRG 970.4M
- CRMD 865.2M
- IPO Year
- FWRG 2021
- CRMD 2010
- Fundamental
- Price
- FWRG $15.85
- CRMD $10.98
- Analyst Decision
- FWRG Strong Buy
- CRMD Strong Buy
- Analyst Count
- FWRG 10
- CRMD 8
- Target Price
- FWRG $22.20
- CRMD $17.57
- AVG Volume (30 Days)
- FWRG 1.2M
- CRMD 2.6M
- Earning Date
- FWRG 11-06-2025
- CRMD 10-29-2025
- Dividend Yield
- FWRG N/A
- CRMD N/A
- EPS Growth
- FWRG N/A
- CRMD N/A
- EPS
- FWRG 0.06
- CRMD 0.79
- Revenue
- FWRG $1,105,027,000.00
- CRMD $121,484,498.00
- Revenue This Year
- FWRG $22.16
- CRMD $480.51
- Revenue Next Year
- FWRG $16.20
- CRMD $59.81
- P/E Ratio
- FWRG $267.84
- CRMD $13.90
- Revenue Growth
- FWRG 14.53
- CRMD 14970.29
- 52 Week Low
- FWRG $12.90
- CRMD $5.60
- 52 Week High
- FWRG $22.71
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- FWRG 40.82
- CRMD 41.63
- Support Level
- FWRG $15.38
- CRMD $11.05
- Resistance Level
- FWRG $16.14
- CRMD $11.71
- Average True Range (ATR)
- FWRG 0.53
- CRMD 0.47
- MACD
- FWRG 0.03
- CRMD 0.01
- Stochastic Oscillator
- FWRG 52.59
- CRMD 8.21
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.